The global infliximab and biosimilar market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The infliximab is a monoclonal anti-tumor necrosis antibody used to treat certain types of arthritis (rheumatoid arthritis, psoriatic arthritis), certain bowel diseases (Crohn’s disease and ulcerative colitis), and serious skin disease (chronic plaque psoriasis). Biosimilar is a medicine that is close in structure and function to a biological drug. The rise in the prevalence of arthritis across the globe is anticipated to drive the growth of the global infliximab and biosimilar market. For instance, according to the data published by the Center for Disease Control and Prevention (CDC) in 2021, the prevalence of doctor-diagnosed arthritis is anticipated to increase in the forthcoming decades. Further, by 2040, approximately 78.4 million adults aged 18 years and older are anticipated to develop doctor-diagnosed arthritis, out of which two-thirds are expected to be women. Further, by 2040, approximately 36.4 million adults are anticipated to report arthritis-attributable activity limitations.
According to the data published by Crohn’s & Colitis Foundation of America (CCFA) in 2019, approximately 1.6 million Americans suffer from Inflammatory Bowel Disease (IBD) out of which 80000 children are expected to have IBD. Further, 70,000 new cases of IBD are diagnosed in the US annually. Moreover, Crohn’s disease and ulcerative diseases are chronic illnesses and changes are likely to occur over time. For instance, as per the same source, 50.0% of the patients suffering from Crohn’s disease will have mild disease over the next five years. 45.0% of those will remain relapse-free over the next year and 35.0% will have one or two relapses. Thus, for a Crohn’s disease patient in remission, the relapses rate at one, two, five, and ten years are estimated at 20.0%, 40.0%, 67.0%, and 76.0% respectively. Thus, the rise in the prevalence of IBD across the globe is anticipated to drive the growth of the infliximab and biosimilar market globally.
Looking towards the demand for infliximab and biosimilar, key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in February 2022, Amneal Pharmaceuticals and Kashiv Biosciences have received the USFDA approval for Releuko(filgrastim-ayow) biosimilar. The Releuko biosimilar is anticipated to launch in the third quarter of 2022 as a treatment option for neutropenia, a low blood cell condition experienced by chemotherapy patients.
Additionally, in June 2021, Celltrion Healthcare Canada Ltd. announced the launch of Remsima Sc (CT-P13 SC) with a subcutaneous formulation, for the treatment of adult patients with rheumatoid arthritis (RA). Moreover, in January 2021, Health Canada has granted a notice for compliance (NOC) for Remsima SC in Canada for the treatment of rheumatoid arthritis in adults. Thus , such product launches coupled with approvals are anticipated to drive the growth of the market during the forecast period.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Global Infliximab and Biosimilar Market at https://orionmarketreports.com/request-sample/?id=92680&submit=Request+Sample%0D%0A
- Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Route of Administration
- By Product
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape– Merck & Co., Pfizer Inc., Sandoz International GmbH, and Celltrion Healthcare co, Ltd. among others
A full report is available at: https://orionmarketreports.com/global-infliximab-and-biosimilar-market/92680/
Global Infliximab and biosimilar market Report by Segment
By Route of Administration
- Subcutaneous
- Intravenous
- Parenteral
- Molecules Type
By Product
- Mono
- combination
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
